New drug pacritinib takes on standard therapy for rare leukemia
NCT ID NCT07033598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares pacritinib to the standard drug hydroxyurea in 66 adults with advanced proliferative chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib improves blood cell counts, reduces spleen size, and controls symptoms better than hydroxyurea. Participants take either drug for up to 48 weeks and are followed for a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pacritinib
- What this could lead to
- If pacritinib works better than hydroxyurea, it could offer a new treatment option for people with advanced chronic myelomonocytic leukemia, potentially improving blood counts and reducing spleen size.
- What could go wrong
- This is a phase 2 trial with only 66 participants, so results are still early. Pacritinib may not prove more effective than hydroxyurea, and side effects could be similar or worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Winship Cancer Institute at Emory
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.